🚀 VC round data is live in beta, check it out!
Bioxyne Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioxyne and similar public comparables like Eurofins-Cerep, Pyxis Oncology, Cognition Therapeutics, OKYO Pharma and more.
Bioxyne Overview
About Bioxyne
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
Founded
1998
HQ
Employees
16
Website
Sectors
Financials (FY)
EV
$91M
Bioxyne Financials
Bioxyne reported last fiscal year revenue of $20M and EBITDA of $3M.
In the same fiscal year, Bioxyne generated $7M in gross profit, $3M in EBITDA, and $3M in net income.
Bioxyne P&L
In the most recent fiscal year, Bioxyne reported revenue of $20M and EBITDA of $3M.
Bioxyne expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $20M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $7M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA | — | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 14% | XXX | XXX | XXX |
| Net Profit | — | XXX | $3M | XXX | XXX | XXX |
| Net Margin | — | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioxyne Stock Performance
Bioxyne has current market cap of $93M, and enterprise value of $91M.
Market Cap Evolution
Bioxyne's stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $91M | $93M | — | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioxyne Valuation Multiples
Bioxyne trades at 4.6x EV/Revenue multiple, and 29.4x EV/EBITDA.
Bioxyne Financial Valuation Multiples
As of March 29, 2026, Bioxyne has market cap of $93M and EV of $91M.
Equity research analysts estimate Bioxyne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioxyne has a P/E ratio of 27.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $93M | XXX | $93M | XXX | XXX | XXX |
| EV (current) | $91M | XXX | $91M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 29.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 32.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 12.8x | XXX | XXX | XXX |
| P/E | — | XXX | 27.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 31.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioxyne Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bioxyne Margins & Growth Rates
Bioxyne's revenue in the last fiscal year grew by 51%.
Bioxyne Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 51% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 217% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bioxyne Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eurofins-Cerep | XXX | XXX | XXX | XXX | XXX | XXX |
| Pyxis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Cognition Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OKYO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eco Animal Health Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioxyne M&A Activity
Bioxyne acquired XXX companies to date.
Last acquisition by Bioxyne was on XXXXXXXX, XXXXX. Bioxyne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bioxyne
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioxyne Investment Activity
Bioxyne invested in XXX companies to date.
Bioxyne made its latest investment on XXXXXXXX, XXXXX. Bioxyne invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bioxyne
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioxyne
| When was Bioxyne founded? | Bioxyne was founded in 1998. |
| Where is Bioxyne headquartered? | Bioxyne is headquartered in Australia. |
| How many employees does Bioxyne have? | As of today, Bioxyne has over 16 employees. |
| Is Bioxyne publicly listed? | Yes, Bioxyne is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Bioxyne? | Bioxyne trades under BXN ticker. |
| When did Bioxyne go public? | Bioxyne went public in 2000. |
| Who are competitors of Bioxyne? | Bioxyne main competitors are Eurofins-Cerep, Pyxis Oncology, Cognition Therapeutics, OKYO Pharma. |
| What is the current market cap of Bioxyne? | Bioxyne's current market cap is $93M. |
| What is the current revenue of Bioxyne? | Bioxyne's last fiscal year revenue is $20M. |
| What is the current EV/Revenue multiple of Bioxyne? | Current revenue multiple of Bioxyne is 4.6x. |
| Is Bioxyne profitable? | No, Bioxyne is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.